Online inquiry

IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15527MR)

This product GTTS-WQ15527MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TGM2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001323316.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7052
UniProt ID P21980
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15527MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15616MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ9388MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ9250MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ4994MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ14455MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ14014MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ12018MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ13951MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW